Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Equities

Amgen Bets Its Obesity Push on MariTide Ahead of Tuesday’s Earnings, With Analysts Seeing $6 Billion in Annual Sales by 2035

by Team Lumida
November 2, 2026
in Equities
Reading Time: 3 mins read
A A
0
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • MariTide is Amgen’s big swing. The monthly weight-loss shot is the most closely watched drug in Amgen’s pipeline and could be the biggest product in its history, in an obesity market expected to surpass $120 billion in annual sales, Bloomberg reports.
  • Earnings will bring scrutiny. Amgen will face questions when it reports earnings Tuesday about whether MariTide will measure up against rivals Eli Lilly and Novo Nordisk, with BMO’s Evan Seigerman asking, “is the profile differentiated enough to warrant the hype?”
  • Amgen is going all in. In August the company discontinued its only other clinical-stage obesity drug, and it has launched nine late-stage studies of MariTide in weight loss and maintenance, cardiovascular disease and sleep apnea, with details from the first expected next year.
  • The prize is large. Success could mean MariTide sales of $6 billion a year by 2035, according to analysts surveyed by Bloomberg, which would be more than any Amgen drug on the market today.

What Happened?

MariTide was engineered with help from DNA samples from nearly 200,000 Icelanders held by DeCode Genetics, which Amgen bought in 2012 for $415 million. The data showed that lower activity of the GIP receptor was associated with lower body weight, the opposite approach to Lilly, whose GIP-activating route produced Mounjaro and Zepbound. Amgen is developing MariTide as a monthly shot and exploring whether as few as four or six injections a year might work. “Even if it’s a monthly drug, that’s 12 injections per year instead of 52,” said Leerink’s David Risinger.

Why It Matters?

MariTide is not likely to reach consumers until 2028, and less-frequent dosing may not be enough to set it apart as competitors like Pfizer advance their own monthly shots. Early trials also raised questions about gastrointestinal side effects, potency and whether its complex biologic design could make it more expensive. For Amgen shareholders, the drug is the defining test of a genetics-driven research strategy the company has spent more than a decade building.

What’s Next?

Amgen is scaling up manufacturing in Ohio, North Carolina and Puerto Rico, fine-tuning its pitch to insurers and employers, and expanding its AmgenNow direct-to-patient platform for cash-paying patients. Watch Tuesday’s earnings for updates on the MariTide program and launch timeline, and next year’s first late-stage trial data.

Affected Tickers and Coins: AMGN, LLY, NVO, PFE

Source: Bloomberg

Previous Post

Data Center Debt Holders Face Rising Construction Risk as S&P Counts 146 Delayed or Canceled US Projects, Most Tied to Local Opposition

Next Post

Anthropic’s Revised S-1 Shows $17 Billion in Third-Quarter Revenue but a Swing to a $567 Million Operating Loss, Plus $895.4 Billion in Compute Commitments

Recommended For You

Gap Cuts Its Full-Year Sales Outlook to Roughly Flat After Flat Comps, but Shares Rise More Than 11% as Old Navy Shows Progress

by Team Lumida
22 hours ago

Gap lowered its full-year sales outlook to roughly flat and cut adjusted EPS guidance, but shares rose more than 11% Friday on signs of an Old Navy turnaround.

Read more

Intuit to Sell Mailchimp to Berkshire-Backed Bending Spoons for $3.68 Billion, Less Than a Third of the $12 Billion It Paid in 2021

by Team Lumida
22 hours ago

Intuit agreed to sell Mailchimp to Bending Spoons for $3.68 billion, less than a third of the $12 billion it paid in 2021, and cut its fiscal 2027...

Read more

TPG and Corpay Agree to Buy Bill Holdings for About $6 Billion, or $63.25 a Share, With Starboard Backing the Deal

by Team Lumida
22 hours ago

TPG will buy a majority stake in Bill and Corpay a minority interest in a deal valued at about $6 billion, or $63.25 a share, the Wall Street...

Read more

Nvidia Plunges 14%, Completing Its Longest Weekly Losing Streak Since 2008, After a Report the SEC Is Exploring Accounting Issues

by Team Lumida
23 hours ago

Nvidia fell 14% on Friday and closed lower for a seventh straight week, its longest streak since 2008, after Reuters reported an SEC accounting probe.

Read more

Musk Says Ousting Huang Was Like Kicking ‘Michael Jordan Off Your Team,’ Regrets Spending at Least $474 Million on the Midterms and Says Tesla Plans a Model Y With No Steering Wheel

by Team Lumida
3 days ago
Elon Musk Reignites Legal Battle Against OpenAI and Sam Altman

At DealBook, Musk criticized Nvidia’s ousting of Jensen Huang, regretted his midterm spending and said Tesla is building a Model Y with no steering wheel.

Read more

Meta Pauses Its Class C Non-Voting Share Plan, and the $60 Billion Sale Tied to It, While a Pension Fund Lawsuit Heads to an April Trial in Delaware

by Team Lumida
3 days ago
Meta’s Content Moderation Shift: Scale Trumps Twitter-Style Risks

Meta said it will not issue Class C non-voting shares while investors including CalSTRS pursue a lawsuit, delaying a planned $60 billion share sale.

Read more

Nadella Calls Microsoft’s Outlook Outage a ‘Perfect Storm’ Caused by a Latent Bug, Saying AI-Driven ‘Patch Velocity’ Is Destabilizing Old Systems, as the Stock Sits Nearly 9% Off Its Nov. 4 High

by Team Lumida
3 days ago
Microsoft’s AI Empire: Nadella’s Bold Moves and Billion-Dollar Bets

Nadella said Microsoft should have tested before last week’s Outlook outage and warned AI-driven patching is creating instability in older systems.

Read more

Moody’s Cuts Nvidia’s Outlook to Stable From Positive on Governance Concerns After Huang’s Ouster, Saying an Upgrade of Its Aa1 Rating Is Unlikely for 12 to 18 Months

by Team Lumida
3 days ago
The AI Capex Machine Keeps Roaring — Nvidia’s Manufacturing Partner Hon Hai Crushes Estimates as Server Demand Drowns Out Recession Fears

Moody’s lowered Nvidia’s outlook to stable from positive, saying Jensen Huang’s exit has added uncertainty to its strategy and financial policies.

Read more

Palo Alto Networks Jumps 7% After Raising Its Fiscal 2027 Outlook to as Much as $14.57 Billion and Agreeing to Buy AI Startup Applied Compute for $4.5 Billion in Stock

by Team Lumida
3 days ago
Palo Alto Networks Earnings Highlights: Strong Q4 Performance and Strategic Platformization Success

Palo Alto beat estimates, lifted fiscal 2027 guidance and agreed to buy Applied Compute for $4.5 billion in stock, sending shares up more than 7%.

Read more

Anthropic Is Indicated 20% to 26% Above Its $83 IPO Price in Gray Markets, as IG Derivatives Point to a $1.35 Trillion Value and Hyperliquid Perps Trade Near $101

by Team Lumida
3 days ago

Gray markets signal a 20% to 26% pop for Anthropic, with IG implying a $1.35 trillion value and Hyperliquid perpetuals near $101 before Thursday’s debut.

Read more
Next Post

Anthropic’s Revised S-1 Shows $17 Billion in Third-Quarter Revenue but a Swing to a $567 Million Operating Loss, Plus $895.4 Billion in Compute Commitments

Marvell Technology Earnings Highlights: Strong AI-Driven Growth and Positive Outlook

Marvell Makes a $115 Billion All-Stock Bet on Optical AI Networking With a Deal for Lumentum, Offering 4.5 Shares for Each Lumentum Share

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Gavin Newsom: China’s Preferred U.S. Presidential Candidate?

Gavin Newsom: China’s Preferred U.S. Presidential Candidate?

July 2, 2024
China Stimulus: Enough to Sway Markets?

China Stimulus: Enough to Sway Markets?

October 9, 2024
Trump Announces 25% Tariffs on Mexico and Canada, Targeting Border Security and Trade

Trump’s Pushback on EV Trucking Rules Threatens Clean Energy Transition in Heavy-Duty Transport

February 25, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018